Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment

An anti-retroviral, treatment plan technology, applied in the direction of retro RNA virus, antiviral agent, virus, etc., can solve the problem of no HIV vaccine clinical access qualification

Inactive Publication Date: 2014-12-10
VACCINE TECH
View PDF62 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no HIV vaccine has been clinically approved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
  • Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
  • Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0310] 1. The application of a pharmaceutical composition, the pharmaceutical composition comprises a pharmaceutically acceptable carrier and an antigen preparation, the antigen preparation comprises HIV polypeptide or a fragment thereof, and the antigen preparation also comprises Bacillus anthracis lethal factor (LFn) At least residues 34-288 of the N-terminus of the polypeptide to enhance the therapeutic effect of HIV antiretroviral therapy in patients.

[0311] 2. The use of the composition of paragraph 1, wherein the HIV polypeptide or fragment thereof is fused to a LFn polypeptide.

[0312] 3. The use of the composition of paragraph 1 or 2, wherein the composition is administered to a patient in combination with conventional antiretroviral therapy.

[0313] 4. The use of the composition of any of paragraphs 1 to 3, wherein the composition is administered to a patient periodically.

[0314] 5. The use of the composition of any of paragraphs 1 to 4, wherein the composition...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention generally relates to HIV compositions and methods of use. One aspect of the present invention relates to a composition comprising a pharmaceutically acceptable carrier and an antigen preparation, the antigen preparation comprising an HIV polypeptide or fragment thereof and a Bacillus anthracis lethal factor (LF) polypeptide, such as a LFn polypeptide. In some embodiments, the LF polypeptide can be fused or otherwise associated with the HIV polypeptide. Other aspect of the present invention relate to use of vaccine comprising a HIV polypeptide and a Bacillus anthracis lethal factor (LF) polypeptide in methods to enhance efficacy traditional antiretroviral therapy.

Description

technical field [0001] The present invention relates to compositions and methods for vaccination against the HIV (AIDS virus) virus. Specifically, the present invention delivers exogenous HIV viral proteins to the cytosol of cells. The invention also relates to methods used in conjunction with conventional retroviral therapy to facilitate retroviral therapy. [0002] Cross References to Related Applications [0003] This application claims the benefit of US Provisional Patent Application No. 61 / 353,176, filed June 9, 2010, which is incorporated herein by reference. Background technique [0004] About 25 million people living with HIV live in sub-Saharan Africa. In resource-poor settings, restrictive treatment options and the cost of alternative treatment options may expand the limits of antiretroviral treatment (ART) programs 1 . Uganda's current HIV infection rate of 6-10% remains unacceptably high. Most ART regimens available in Uganda are limited to low-cost and fix...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/21A61K39/07A61P31/18
CPCA61K39/07A61K2039/6037A61K39/21C12N2740/16234A61K2039/55505C07K2319/55A61K2039/572A61K39/12A61P31/18A61K2300/00
Inventor 卢毅辰曹玄
Owner VACCINE TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com